Clinical Trials Update from NCI, February 2018

Clinical Trials Update from NCI, February 2018

Clinical Trials
Updates from the National Cancer Institute
Clinical Trials News
		Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia Based on data from two clinical trials, the Food and Drug Administration (FDA) has granted a label change for the drug nilotinib (Tasigna), allowing patients with chronic myelogenous leukemia who have been using nilotinib for at least 3 years and been in remission for an extended period to stop treatment.
		FDA Approves New Treatment for Certain Neuroendocrine Tumors Results from two clinical trials form the basis for the FDA’s approval of a new targeted therapy for adult patients with advanced neuroendocrine tumors that affect the pancreas or gastrointestinal tract, known as GEP-NETs. Lutetium Lu 177 dotatate is the first radioactive drug approved to treat these rare cancers.
		Abiraterone Approved for Earlier Use in Men with Metastatic Prostate Cancer FDA has expanded the approval of abiraterone (Zytiga) for men with prostate cancer based on the results from a large phase 3 trial. The agency approved abiraterone for men with metastatic prostate cancer that is responsive to hormone-blocking treatments (castration-sensitive) and is at high risk of progressing.
		Find NCI-Supported Clinical Trials Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
Clinical Trials Information for Patients and Caregivers
Patient Safety in Clinical Trials This page introduces the issue of patient safety in clinical trials. It includes a video further explaining how trial investigators guarantee patient safety.
Informed Consent Informed consent is a process through which you learn details about the trial before deciding whether to take part. This page explains the informed consent process.
Children's Assent Children cannot legally give consent for treatment. This page discusses how children’s assent is attained for participation in clinical trials.
NCI-Supported Clinical Trials that Are Recruiting Patients
Shortened Course of Radiation After Prostate Surgery This phase 1 study is designed to test a shortened course of highly focused radiation therapy in men with prostate cancer that has returned following surgery to remove all or part of the prostate (prostatectomy). Doctors want to see if the modified radiation therapy regimen can be delivered without increased side effects.
Testing a Blood Cancer Drug in Young Patients with Brain Tumors This phase 2 study is testing the drug palmolidomide in patients between the ages of 1 and 21 who have recurring or progressive primary brain tumors, including high-grade glioma, medulloblastoma, ependymoma, and DIPG. Doctors will assess the efficacy, safety, and tolerability of pomalidomide in these patients following at least one prior therapy.
Experimental Antibody Therapy for Patients with Certain Advanced Cancers This phase 1b study will examine the safety, dosing, and efficacy of anetumab ravtansine as a single agent or in combination with other drugs for patients with mesothelin-expressing advanced solid tumors. Mesothelin is a protein that is often overabundant on cells of some cancer types, including mesothelioma, pancreatic cancer, ovarian cancer, and cholangiocarcinoma.